TY - JOUR
T1 - Complex fibroadenoma and breast cancer risk
T2 - a Mayo Clinic Benign Breast Disease Cohort Study
AU - Nassar, Aziza
AU - Visscher, Daniel W.
AU - Degnim, Amy C.
AU - Frank, Ryan D.
AU - Vierkant, Robert A.
AU - Frost, Marlene
AU - Radisky, Derek C.
AU - Vachon, Celine M.
AU - Kraft, Ruth A.
AU - Hartmann, Lynn C.
AU - Ghosh, Karthik
N1 - Funding Information:
The authors thank T. Allers, J. Johnson, and A. Harris and the Mayo Survey Research Center for data collection. This research was supported by an R01 CA132879 from the National Cancer Institute (Lynn C. Hartmann), the Mayo Clinic Breast Cancer Specialized Programs of Research Excellence (SPOREs) grant CA116201 (Lynn C. Hartmann and Derek C. Radisky), and the Fred C. and Katherine B. Andersen Foundation (Lynn C. Hartmann). The funding sources had no involvement in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the manuscript for publication. The authors are responsible for the content. The content does not necessarily represent the views of the National Institutes of Health.
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/9/7
Y1 - 2015/9/7
N2 - The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18–85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age- and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26–1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63–3.10) (test for heterogeneity in SIR, P = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.
AB - The purpose of this study is to examine the breast cancer risk overall among women with simple fibroadenoma or complex fibroadenoma and to examine the association of complex fibroadenoma with breast cancer through stratification of other breast cancer risks. The study included women aged 18–85 years from the Mayo Clinic Benign Breast Disease Cohort who underwent excisional breast biopsy from 1967 through 1991. Within this cohort, women who had fibroadenoma were compared to women who did not have fibroadenoma. Breast cancer risk (observed versus expected) across fibroadenoma levels was assessed through standardized incidence ratios (SIRs) by using age- and calendar-stratified incidence rates from the Iowa Surveillance, Epidemiology, and End Results registry. Analyses were performed overall, within subgroups of involution status, with other demographic characteristics (age, year of biopsy, indication for biopsy, and family history), and with histologic characteristics, including overall impression [nonproliferative disease, proliferative disease without atypia (PDWA), or atypical hyperplasia]. Fibroadenoma was identified in 2136 women [noncomplex, 1835 (85.9 %); complex, 301 (14.1 %)]. SIR for noncomplex fibroadenoma was 1.49 (95 % CI 1.26–1.74); for complex fibroadenoma, it was 2.27 (95 % CI 1.63–3.10) (test for heterogeneity in SIR, P = .02). However, women with complex fibroadenoma were more likely to have other, concomitant high-risk histologic characteristics (e.g., incomplete involution and PDWA). In analyses stratified by involution status and PDWA, complex fibroadenoma was not an independent risk marker for breast cancer. Complex fibroadenoma does not confer increased breast cancer risk beyond other established histologic characteristics.
KW - Benign breast disease
KW - Breast cancer
KW - Cancer risk
KW - Fibroadenoma
KW - Mayo Clinic benign breast disease cohort
UR - http://www.scopus.com/inward/record.url?scp=84940963054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940963054&partnerID=8YFLogxK
U2 - 10.1007/s10549-015-3535-8
DO - 10.1007/s10549-015-3535-8
M3 - Article
C2 - 26264469
AN - SCOPUS:84940963054
VL - 153
SP - 397
EP - 405
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 2
ER -